Developer docs
API playgroundTry for free, no card

Search company profiles

Solvias

Full company profile

uuid0006dp3

Namestring
Solvias
Legal namestring
Solvias AG
Websiteurl
solvias.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Solvias AG is a Switzerland-headquartered contract research organization (CRO) spun out of Novartis in 1999, providing cGMP-compliant CMC (Chemistry, Manufacturing, and Controls) analytical services to the pharmaceutical, biotech, medical-device, and cosmetics industries. Its core technology stack spans chromatography (HPLC, UPLC, CE), mass spectrometry (LC-MS, GC-MS, HRAM), spectroscopy, molecular biology, and biosafety methods, complemented by the proprietary Targeted Locus Amplification (TLA) platform acquired with Cergentis in 2022. The service portfolio covers analytical method development and validation, drug substance and drug product release testing (with stated 10-15 day turnaround), extractables and leachables testing, biosafety, stability testing (600+ programs over 20+ years), container closure integrity testing, cell-based bioassays, impurity and nitrosamine testing, and genetic quality control for biologics and ATMPs (supported by ~3,800 GMP-compliant tests annually and released commercial support for 4 ATMPs and 2 biologics).

The business operates on a B2B professional-services model, selling fixed-price and time-and-materials analytical engagements to enterprise pharmaceutical and biotech clients via direct field sales, consultative subject-matter-expert engagement, and channels including CPHI conferences, white papers, and webinars. Solvias reports 700+ customers worldwide and 19 of the top 20 pharma companies as clients, delivered through 5-6 Centers of Excellence (Kaiseraugst CH headquarters, Hombourg FR, Utrecht NL, Canton MA, Morrisville NC RTP). Talent depth is a stated differentiator, with 175+ PhD-level scientists on an ~800-person base, and revenue is captured through project-based service fees for drug development phases spanning preclinical through commercial.

Ownership and capital structure center on JLL Partners, a middle-market private equity firm that invested through its $1.4 billion Fund IX (2026). Solvias executed three acquisitions over the past decade (Confarma 2013, Chemic 2021, Cergentis 2022), expanded U.S. capacity with a 2025 RTP Center of Excellence for Biologics & CGT, and rolled out a new ERP (2024) following a 2023 LIMS deployment. Regulatory positioning includes Swissmedic, ANSM, and FDA GMP certifications, ISO 17025/9001/14001/45001/26000, DEA licensing, MIA certification, and an EcoVadis Bronze Medal (2026).

Short descriptiontext

Solvias AG is a Switzerland-based cGMP contract research organization providing CMC analytical services — including method development, release testing, stability, biosafety, extractables & leachables, and genetic QC via proprietary TLA technology — to 700+ pharmaceutical, biotech, and medical-device clients across 6 European and U.S. Centers of Excellence.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersKaiseraugst, Switzerland
HQ citystring
Kaiseraugst
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, pharmaceutical analytical testing, cGMP release testing, CMC analytics, cell and gene therapy testing
Industry2 codes
PRIMARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Pharmaceutical Analytical Testing & CMC Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research and Testing Services
TypeProfessional Services
Description

Solvias generates revenue through providing cGMP-compliant analytical testing, method development, validation, and release testing services on a project-by-project basis. Services are contracted for specific drug development phases from preclinical through commercial. Revenue is earned through service fees, typically structured as fixed-price projects or time-and-materials contracts with pharmaceutical and biotech clients.

solvias.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Targeted Locus Amplification (TLA)
Description

Proprietary technology platform for genetic quality control, enabling complete and targeted gene sequencing for detection of single nucleotide variants and structural variants.

solvias.com
Core offering1 text field

Solvias is a global cGMP contract research organization providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytical services for pharmaceutical, biotech, medical device, and cosmetics companies. The company delivers method development and validation, drug substance and drug product release testing, stability studies, extractables and leachables testing, biosafety testing, genetic quality control, cell-based bioassays, and impurity analysis across small molecules, biologics, and cell and gene therapies. Services are delivered through six Centers of Excellence in Switzerland, France, the Netherlands, and the United States, with proprietary Targeted Locus Amplification (TLA) technology supporting genetic characterization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 10-15 day turnaround for full panel drug substance and drug product release testing
+4 more records
Product overview1 text field

Solvias is a global contract research organization (CRO) providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytics services. The company offers a unified platform of analytical testing and characterization services spanning the entire drug development journey from research through commercialization. The core portfolio includes Analytical Method Development & Validation, cGMP Drug Substance & Drug Product Testing & Release, Extractables & Leachables Testing, Biosafety Testing, Stability Testing, and Container Closure Integrity Testing (CCIT). The company also provides specialized services including Genetic Quality Control Testing powered by proprietary Targeted Locus Amplification (TLA) technology, Cell-Based Bioassays, and Impurity Testing & Contamination Control. For small molecules, Solvias offers API development and manufacturing capabilities alongside Process Analytical Technology (PAT) products including fiber optic probes. The service offering is delivered across six global Centers of Excellence in Switzerland, France, Netherlands, and the United States, with expertise covering biologics, cell & gene therapies, and small molecules.

Product and service13 records
1Analytical Method Development & Validation
CategoryAnalytical Services
2cGMP Drug Substance & Drug Product Testing & Release
CategoryAnalytical Services
3Analytical Characterization Services
CategoryAnalytical Services
4Extractables & Leachables Testing
CategoryAnalytical Services
5Stability Testing
CategoryAnalytical Services
6Biosafety Testing
CategoryAnalytical Services
7Impurity Testing & Contamination Control
CategoryAnalytical Services
8Container Closure Integrity Testing (CCIT)
CategoryAnalytical Services
Description

Deterministic and probabilistic CCIT solutions including vacuum decay, pressure decay, dye ingress, and microbial ingress testing aligned with USP <1207>, EU GMP Annex 1, and PDA Technical Report 27.

9Excipient & Raw Materials Testing and Release
CategoryAnalytical Services
10Cell-Based Bioassays
CategoryAnalytical Services
11Genetic Quality Control Testing
CategoryAnalytical Services
12Ligands & Catalysts
CategoryProducts
13Process Analytical Technology (PAT)
CategoryProducts
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global testing services provider with pharmaceutical services including analytical method development, stability, impurity and E&L testing. Directly comparable CMC analytical testing offering for the same regulated pharmaceutical customers.

TypeDirect peer
Description

Global testing-services leader with deep pharmaceutical product testing, bioanalytical, and cosmetics practices. Directly competes with Solvias across CMC analytical testing, release testing, stability, extractables and leachables, and biosafety for pharma and biotech customers.

TypeBroad incumbent
Description

Global clinical and bioanalytical CRO with biopharma services. Overlaps Solvias in pharmaceutical testing services as part of a clinical-development-oriented portfolio.

TypeBroad incumbent
Description

Global CRO through PPD plus bioanalytical and central lab services. Offers overlapping CMC testing for biologics and cell therapies within a much broader life sciences tools and services portfolio.

TypeBroad incumbent
Description

Major global CRO with central lab and bioanalytical capabilities after the PRA Health Sciences acquisition. Competes in pharma testing services with a clinical-trial-tilted portfolio.

TypeBroad incumbent
Description

Largest global CRO with R&D Solutions laboratory and bioanalytical services covering CMC and clinical testing. Competes with Solvias in pharma analytics as part of a much broader CRO and data services portfolio.

TypeDirect peer
Description

Global CRO/CDMO offering comprehensive analytical and CMC services including biologics testing and CGT characterization. Directly competitive with Solvias on small molecule, biologics, and cell and gene therapy analytical engagements.

TypeBroad incumbent
Description

Global CRO via Covance plus central and biopharma lab services. Overlaps Solvias in CMC and bioanalytical work while also offering clinical trial laboratory and broader diagnostic testing.

TypeBroad incumbent
Description

Large global CRO with Biologics Services, Cell & Gene Therapy, and Discovery/Safety operations. Overlaps Solvias in analytical testing, CGT characterization, and biosafety testing while also serving broader preclinical and manufacturing needs.

TypeDirect peer
Description

Major global testing services group with a sizeable pharmaceutical analytical services practice covering method development, validation, stability, and impurity testing. Directly comparable scope in CMC and quality control services for pharma and biotech.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance11 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Solvias

Pharmaceutical Analytical Testing & CMC Servicessolvias.com

Solvias AG is a Switzerland-based cGMP contract research organization providing CMC analytical services — including method development, release testing, stability, biosafety, extractables & leachables, and genetic QC via proprietary TLA technology — to 700+ pharmaceutical, biotech, and medical-device clients across 6 European and U.S. Centers of Excellence.

What Solvias does

Solvias AG is a Switzerland-headquartered contract research organization (CRO) spun out of Novartis in 1999, providing cGMP-compliant CMC (Chemistry, Manufacturing, and Controls) analytical services to the pharmaceutical, biotech, medical-device, and cosmetics industries. Its core technology stack spans chromatography (HPLC, UPLC, CE), mass spectrometry (LC-MS, GC-MS, HRAM), spectroscopy, molecular biology, and biosafety methods, complemented by the proprietary Targeted Locus Amplification (TLA) platform acquired with Cergentis in 2022. The service portfolio covers analytical method development and validation, drug substance and drug product release testing (with stated 10-15 day turnaround), extractables and leachables testing, biosafety, stability testing (600+ programs over 20+ years), container closure integrity testing, cell-based bioassays, impurity and nitrosamine testing, and genetic quality control for biologics and ATMPs (supported by ~3,800 GMP-compliant tests annually and released commercial support for 4 ATMPs and 2 biologics).

The business operates on a B2B professional-services model, selling fixed-price and time-and-materials analytical engagements to enterprise pharmaceutical and biotech clients via direct field sales, consultative subject-matter-expert engagement, and channels including CPHI conferences, white papers, and webinars. Solvias reports 700+ customers worldwide and 19 of the top 20 pharma companies as clients, delivered through 5-6 Centers of Excellence (Kaiseraugst CH headquarters, Hombourg FR, Utrecht NL, Canton MA, Morrisville NC RTP). Talent depth is a stated differentiator, with 175+ PhD-level scientists on an ~800-person base, and revenue is captured through project-based service fees for drug development phases spanning preclinical through commercial.

Ownership and capital structure center on JLL Partners, a middle-market private equity firm that invested through its $1.4 billion Fund IX (2026). Solvias executed three acquisitions over the past decade (Confarma 2013, Chemic 2021, Cergentis 2022), expanded U.S. capacity with a 2025 RTP Center of Excellence for Biologics & CGT, and rolled out a new ERP (2024) following a 2023 LIMS deployment. Regulatory positioning includes Swissmedic, ANSM, and FDA GMP certifications, ISO 17025/9001/14001/45001/26000, DEA licensing, MIA certification, and an EcoVadis Bronze Medal (2026).

Solvias firmographics

Firmographics
Name
Solvias
Legal name
Solvias AG
Website
https://solvias.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Solvias AG is a Switzerland-based cGMP contract research organization providing CMC analytical services — including method development, release testing, stability, biosafety, extractables & leachables, and genetic QC via proprietary TLA technology — to 700+ pharmaceutical, biotech, and medical-device clients across 6 European and U.S. Centers of Excellence.
Ownership category
akta.pro rank

Solvias industry classification

Industry
Product category
Pharmaceutical Analytical Testing & CMC Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAKAI
Clinical Quality Assurance (GCP QA, TMF/QMS oversight)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Contract research services
  • Pharmaceutical analytical testing
  • CGMP release testing
  • CMC analytics
  • Cell and gene therapy testing

Where Solvias is headquartered

Location

Headquarters

HQ city
Kaiseraugst
HQ country
Switzerland
HQ region
Europe

Offices5 records

Markets served

Solvias business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Contract Research and Testing Services: Solvias generates revenue through providing cGMP-compliant analytical testing, method development, validation, and release testing services on a project-by-project basis. Services are contracted for specific drug development phases from preclinical through commercial. Revenue is earned through service fees, typically structured as fixed-price projects or time-and-materials contracts with pharmaceutical and biotech clients.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Solvias product offering

Product offering

Core offering

Solvias is a global cGMP contract research organization providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytical services for pharmaceutical, biotech, medical device, and cosmetics companies. The company delivers method development and validation, drug substance and drug product release testing, stability studies, extractables and leachables testing, biosafety testing, genetic quality control, cell-based bioassays, and impurity analysis across small molecules, biologics, and cell and gene therapies. Services are delivered through six Centers of Excellence in Switzerland, France, the Netherlands, and the United States, with proprietary Targeted Locus Amplification (TLA) technology supporting genetic characterization.

Product overview

Solvias is a global contract research organization (CRO) providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytics services. The company offers a unified platform of analytical testing and characterization services spanning the entire drug development journey from research through commercialization. The core portfolio includes Analytical Method Development & Validation, cGMP Drug Substance & Drug Product Testing & Release, Extractables & Leachables Testing, Biosafety Testing, Stability Testing, and Container Closure Integrity Testing (CCIT). The company also provides specialized services including Genetic Quality Control Testing powered by proprietary Targeted Locus Amplification (TLA) technology, Cell-Based Bioassays, and Impurity Testing & Contamination Control. For small molecules, Solvias offers API development and manufacturing capabilities alongside Process Analytical Technology (PAT) products including fiber optic probes. The service offering is delivered across six global Centers of Excellence in Switzerland, France, Netherlands, and the United States, with expertise covering biologics, cell & gene therapies, and small molecules.

Differentiator

Problem solved

Functional benefit

Brands

  • Targeted Locus Amplification (TLA): Proprietary technology platform for genetic quality control, enabling complete and targeted gene sequencing for detection of single nucleotide variants and structural variants.

Products and services

  • Analytical Method Development & Validation
  • cGMP Drug Substance & Drug Product Testing & Release
  • Analytical Characterization Services
  • Extractables & Leachables Testing
  • Stability Testing
  • Biosafety Testing
  • Impurity Testing & Contamination Control
  • Container Closure Integrity Testing (CCIT) Deterministic and probabilistic CCIT solutions including vacuum decay, pressure decay, dye ingress, and microbial ingress testing aligned with USP <1207>, EU GMP Annex 1, and PDA Technical Report 27.
  • Excipient & Raw Materials Testing and Release
  • Cell-Based Bioassays
  • Genetic Quality Control Testing
  • Ligands & Catalysts
  • Process Analytical Technology (PAT)

Quantifiable outcome

  • 10-15 day turnaround for full panel drug substance and drug product release testing
  • +4 more outcomes

Companies that use Solvias

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Solvias technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Solvias partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Solvias competitors and assessment

Company assessment

Direct peers

  • Intertek Life Sciences: Global testing services provider with pharmaceutical services including analytical method development, stability, impurity and E&L testing. Directly comparable CMC analytical testing offering for the same regulated pharmaceutical customers.
  • Eurofins Scientific: Global testing-services leader with deep pharmaceutical product testing, bioanalytical, and cosmetics practices. Directly competes with Solvias across CMC analytical testing, release testing, stability, extractables and leachables, and biosafety for pharma and biotech customers.
  • WuXi AppTec: Global CRO/CDMO offering comprehensive analytical and CMC services including biologics testing and CGT characterization. Directly competitive with Solvias on small molecule, biologics, and cell and gene therapy analytical engagements.
  • SGS Life Sciences: Major global testing services group with a sizeable pharmaceutical analytical services practice covering method development, validation, stability, and impurity testing. Directly comparable scope in CMC and quality control services for pharma and biotech.

Broad incumbents

  • Syneos Health: Global clinical and bioanalytical CRO with biopharma services. Overlaps Solvias in pharmaceutical testing services as part of a clinical-development-oriented portfolio.
  • Thermo Fisher Scientific (PPD): Global CRO through PPD plus bioanalytical and central lab services. Offers overlapping CMC testing for biologics and cell therapies within a much broader life sciences tools and services portfolio.
  • ICON plc: Major global CRO with central lab and bioanalytical capabilities after the PRA Health Sciences acquisition. Competes in pharma testing services with a clinical-trial-tilted portfolio.
  • IQVIA: Largest global CRO with R&D Solutions laboratory and bioanalytical services covering CMC and clinical testing. Competes with Solvias in pharma analytics as part of a much broader CRO and data services portfolio.
  • Labcorp (Covance Drug Development): Global CRO via Covance plus central and biopharma lab services. Overlaps Solvias in CMC and bioanalytical work while also offering clinical trial laboratory and broader diagnostic testing.
  • Charles River Laboratories: Large global CRO with Biologics Services, Cell & Gene Therapy, and Discovery/Safety operations. Overlaps Solvias in analytical testing, CGT characterization, and biosafety testing while also serving broader preclinical and manufacturing needs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Solvias social profiles

Digital presence

Solvias compliance and trust

Trust signal

Compliance11 records

Solvias financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Solvias leadership team

Management profile

Number of profiles

Profiles1 record

Solvias subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Solvias funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Solvias M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Solvias

What does Solvias do?

Solvias is a global cGMP contract research organization providing comprehensive CMC (Chemistry, Manufacturing, and Controls) analytical services for pharmaceutical, biotech, medical device, and cosmetics companies. The company delivers method development and validation, drug substance and drug product release testing, stability studies, extractables and leachables testing, biosafety testing, genetic quality control, cell-based bioassays, and impurity analysis across small molecules, biologics, and cell and gene therapies. Services are delivered through six Centers of Excellence in Switzerland, France, the Netherlands, and the United States, with proprietary Targeted Locus Amplification (TLA) technology supporting genetic characterization.

Is Solvias a public or private company?

Solvias is a private company. It is classified as private equity controlled and is currently operating.

When was Solvias founded?

Solvias was founded in 1999. It employs 501 to 1,000 people.

Where is Solvias based?

Solvias is headquartered in Kaiseraugst, Switzerland, in the Europe region.

How does Solvias make money?

One revenue line is on record: contract Research and Testing Services.

Who are Solvias's main competitors?

Direct peers on record are Intertek Life Sciences, Eurofins Scientific, WuXi AppTec and SGS Life Sciences. Broad incumbents are Syneos Health, Thermo Fisher Scientific (PPD), ICON plc, IQVIA, Labcorp (Covance Drug Development) and Charles River Laboratories.

Does Solvias have an API?

No public API is recorded for Solvias.

What industry is Solvias in?

Solvias's product category is Pharmaceutical Analytical Testing & CMC Services. Its primary akta.pro industry code is HLAGAHAM, Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC), with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSolvias erhält die EcoVadis-Bronzemedaille und gehört damit zu den 35% der Unternehmen mit der besten NachhaltigkeitsleistungSolvias, a global CMC analysis provider for the life sciences industry headquartered in Switzerland, has been awarded the EcoVadis Bronze Medal, placing it among the top 35% of over 100,000 companies rated worldwide. The recognition reflects Solvias' continuous progress in strengthening responsible business practices across its operations and value chain, following the company's first EcoVadis assessment in 2025. The company has implemented a sustainability framework since 2024, including calculating its carbon footprint (Scopes 1-3) and establishing a five-year ESG roadmap.PR NewswireSolvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability PerformanceSolvias, a global CMC analytics provider for the life sciences industry headquartered near Basel, Switzerland, has earned a Bronze Medal from EcoVadis, placing the company in the top 35% of more than 100,000 companies evaluated worldwide. The recognition reflects Solvias' progress since launching its ESG initiative in 2024, which includes calculating corporate carbon footprint across Scopes 1–3, establishing sustainability targets, and implementing a five-year ESG roadmap. The company, which received a Committed Badge in its first EcoVadis assessment in 2025, aims to further align with frameworks such as the Science Based Targets initiative while supporting innovation in drug development and sustainable healthcare supply chains.PR NewswireSolvias Earns EcoVadis Bronze Medal, Ranking in Top 35% of Companies for Sustainability PerformanceSolvias, a global provider of chemistry, manufacturing, and controls (CMC) analytics for the life sciences industry, has earned an EcoVadis Bronze Medal, ranking in the top 35% of more than 100,000 companies evaluated worldwide. The recognition reflects the company's progress in environmental, social, and governance (ESG) initiatives since launching its sustainability framework in 2024, building on an initial Committed Badge received in 2025. Solvias, headquartered near Basel, Switzerland, operates five global Centers of Excellence serving pharmaceutical and biotech companies across small molecules, biologics, and novel modalities.MorningstarWhat Will Define the Future of Pharma? Five Trends on Solvias' Radar Ahead of CPHI Frankfurt 2025Solvias outlines five trends expected at CPHI Frankfurt 2025, including AI and big data in analytics, advanced mass spectrometry in GMP, CMC as a critical pathway, oral GLP-1 small molecules, and smarter drug delivery. The company highlights oral GLP-1s like Eli Lilly's Orforglipron as a market-shaping development by 2026.PR NewswireWhat Will Define the Future of Pharma? Five Trends on Solvias' Radar Ahead of CPHI Frankfurt 2025Solvias outlines five trends expected at CPHI Frankfurt 2025, including AI and big data in analytics, advanced mass spectrometry in GMP, CMC as a critical pathway, oral GLP-1 small molecules, and smarter drug delivery. The company highlights oral GLP-1s like Eli Lilly's Orforglipron as a market-shaping development by 2026.DatainteloChiral Phase Transfer Catalyst Market Research Report 2033The global Chiral Phase Transfer Catalyst market is projected to grow from USD 128.6 million in 2024 to USD 255.5 million by 2033, driven by demand for enantioselective synthesis in pharmaceuticals and agrochemicals. Asia Pacific is identified as the fastest-growing region, while key industry players include Solvias AG, Merck KGaA, and BASF SE.YahooSolvias to Present at Cell & Gene Therapy International 2025 on Multilayered Quality Control in CGT ManufacturingSolvias will present at Cell & Gene Therapy International 2025 in Boston on multilayered quality control in CGT manufacturing. The session highlights NGS-based strategies for vector fidelity, adventitious virus detection, and epigenetic testing. The presentation aims to help developers strengthen product reliability and meet regulatory expectations.PR NewswireSolvias to Present at Cell & Gene Therapy International 2025 on Multilayered Quality Control in CGT ManufacturingSolvias will present at the Cell & Gene Therapy International (CGTI) 2025 conference in Boston, Massachusetts, from September 16–18, showcasing advanced quality control strategies in cell and gene therapy manufacturing. The presentation, led by William Mauck, will focus on innovative analytical methods that tackle challenges in CGT manufacturing while emphasizing robust quality control processes. This event highlights Solvias' commitment to enhancing product reliability and meeting regulatory expectations in the life sciences industry.WeilWeil Advises JLL Partners in Formation of Continuation Fund to Extend Investment in Solvias AGWeil is advising JLL Partners on forming a continuation fund to extend its investment in Solvias AG, a Swiss contract pharmaceutical company. JLL Partners is a middle-market private equity firm with over three decades of experience in healthcare, specialty industrials, and business services.WsjExclusive | JLL Partners Attracts TPG to Back $1.1 Billion Continuation Fund for SolviasJLL Partners is extending its ownership of Solvias, a contract pharmaceuticals researcher and manufacturer, through a continuation fund. Lead investors TPG and Pantheon made commitments through their own secondary investment funds, with earlier JLL fund investors able to remain invested or cash out.